Veritas In Silico (TYO:130A) has launched its first in-house drug project targeting acute kidney injury after cardiovascular surgery, using an mRNA-targeted nucleic acid drug, according to a Monday filing on the Tokyo Stock Exchange.
The treatment, described as first-in-class, targets high-risk patients aged 65 and older in Japan, with peak domestic sales estimated at 15 billion yen.
Development is estimated within eight to 10 years. The drug will be developed using Veritas' ibVIS platform. The company may commercialize the treatment independently or through licensing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。